Overview
DiogenX is a pioneering biotech company established in 2020, dedicated to the regeneration of insulin-producing beta cells for diabetes treatment. With headquarters in Marseille, France, and research laboratories in Nice, France, DiogenX operates as a preclinical stage company. Their mission centers on developing innovative biologics that serve as novel therapeutic options for millions of diabetic patients globally. The company's research is grounded in the accomplishments of Patrick Collombat, a leading scientist in Type 1 Diabetes (T1D). DiogenX's flagship program, DGX-01, targets the Wnt/β-catenin signaling pathway to regenerate insulin-producing pancreatic cells and is currently in the IND-enabling study phase.
Executive Leadership and Board of Directors
Benjamin Charles, CEO and co-founder of DiogenX, played a pivotal role in founding the company. His prior experience includes co-founding Imcheck, which focuses on gamma delta T-cell immunomodulation. He possesses a PharmD and an MBA from Essec Business School.
Patrick Collombat, co-founder and scientific advisor, is a PhD scholar from the Max-Planck Institute for Biophysical Chemistry, renowned for his work on pancreatic insulin-producing beta-cell neogenesis and recipient of honors like the JDRF Career Development Award.
Hélène Sicard, Chief Development Officer, holds a PhD in molecular biology from Toulouse Paul Sabatier University, significantly contributing to DiogenX's developmental efforts on their lead candidate, DGX-01.
Klara Owen, Chief Medical Officer, brings in-depth expertise in T1D and metabolic disorders from her tenure in larger pharmaceutical enterprises.
The Board of Directors includes notable individuals:
- Glyn Parkin, Independent Chairman
- Katie Ellias, Managing Director at JDRF T1D Fund
- David Evans, Investor Director at Roche Venture Fund
- Johannes Zanzinger, representing the Boehringer Ingelheim Venture Fund GmbH
Funding and Strategic Growth
DiogenX achieved a key financial milestone by securing €27.5 million ($30 million) in Series A funding in May 2023, supported by leading figures in diabetes and biopharma including the Boehringer Ingelheim Venture Fund, Roche Venture Fund, and Eli Lilly and Company. This significant investment is dedicated to advancing DiogenX’s innovative regenerative treatment for T1D into clinical trials, a critical phase in their developmental pathway.
Strategic Mission and Vision
DiogenX aims to transform diabetes management by focusing on pancreatic beta-cell regeneration, intending to provide a disease-modifying solution for T1D. The company's strategy intertwines rigorous scientific research with targeted financial investments, reinforcing their dedication to addressing critical unmet medical needs and improving patient outcomes globally through their expert team and strategic partnerships.
Competitor Analysis
In the competitive biotech sector, DiogenX faces significant rivalry, especially from major corporations such as AstraZeneca, Boehringer Ingelheim, and GSK. Other notable competitors include Orgenesis and Poxel, each offering unique approaches and solutions in therapeutics for diabetes:
1. AstraZeneca: A global biopharmaceutical leader known for its substantial investment in R&D and strong market presence, particularly in oncology and diabetes-related research.
2. Boehringer Ingelheim: This large, privately-held pharmaceutical firm focuses on innovative health solutions in Human Pharma and Animal Health, providing broad competitive offerings in diabetes management.
3. GSK: Renowned for its proactive approach in healthcare innovation, GSK develops vaccines and medicines that address various health conditions, elevating its presence in diabetes treatment.
4. Orgenesis: Specializes in cell and gene therapy through its POCare™ platform, seeking scalable and decentralized healthcare solutions.
5. Poxel: Concentrates on metabolic diseases and disorders, with a strong focus on diabetes treatment through novel therapeutic modalities.
Investment and Backing
DiogenX is strongly supported by prominent investors, including the Roche Venture Fund, Eli Lilly and Company, Boehringer Ingelheim Venture Fund, JDRF T1D Fund, and AdBio partners. This robust investment base not only upholds DiogenX’s financial foundation but also synchronizes them with strategic leaders in the pharmaceutical and biotherapeutics market.
Outlook
DiogenX seeks to navigate the dynamic biotech industry where capturing market share and carving out innovation space amidst formidable competitors remains essential. The advancement of their clinical pipeline and strategic investor collaborations are key components driving DiogenX’s influence and reach within the diabetes care sector.
